736 related articles for article (PubMed ID: 28793863)
1. Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N
BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863
[TBL] [Abstract][Full Text] [Related]
2. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
Ahmed MH; Al-Atta A; Hamad MA
Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
[TBL] [Abstract][Full Text] [Related]
3. Treatment of dyslipidemia in HIV.
Sekhar RV
Curr Atheroscler Rep; 2015 Apr; 17(4):493. PubMed ID: 25702057
[TBL] [Abstract][Full Text] [Related]
4. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
[TBL] [Abstract][Full Text] [Related]
5. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
6. Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.
Bednasz C; Luque AE; Zingman BS; Fischl MA; Gripshover BM; Venuto CS; Gu J; Feng Z; DiFrancesco R; Morse GD; Ma Q
Curr Vasc Pharmacol; 2016; 14(3):280-7. PubMed ID: 26733388
[TBL] [Abstract][Full Text] [Related]
7. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
[TBL] [Abstract][Full Text] [Related]
8. The role of statins in the setting of HIV infection.
Eckard AR; McComsey GA
Curr HIV/AIDS Rep; 2015 Sep; 12(3):305-12. PubMed ID: 26126687
[TBL] [Abstract][Full Text] [Related]
9. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.
Troll JG
Curr Atheroscler Rep; 2011 Feb; 13(1):51-6. PubMed ID: 21181310
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy with heart.
Randell P; Moyle G
Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
[TBL] [Abstract][Full Text] [Related]
11. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
Sension M; Deckx H
AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular implications of HIV-induced dyslipidemia.
Giannarelli C; Klein RS; Badimon JJ
Atherosclerosis; 2011 Dec; 219(2):384-9. PubMed ID: 21722900
[TBL] [Abstract][Full Text] [Related]
13. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
[TBL] [Abstract][Full Text] [Related]
14. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
15. Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?
Stein JH
Top Antivir Med; 2016 Dec-2017 Jan; 23(5):169-73. PubMed ID: 27398770
[TBL] [Abstract][Full Text] [Related]
16. Drug therapies for HIV-related metabolic disorders.
Lamarca K; García Sarasola A; Vidal F; Domingo P
Expert Opin Pharmacother; 2016 Jul; 17(10):1327-38. PubMed ID: 27192322
[TBL] [Abstract][Full Text] [Related]
17. Clinical management considerations for dyslipidemia in HIV-infected individuals.
Kirchner JT
Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia: management using optimal lipid-lowering therapy.
Ito MK
Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652
[TBL] [Abstract][Full Text] [Related]
19. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
Leclercq P; Blanc M
Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
[TBL] [Abstract][Full Text] [Related]
20. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]